Based: San Diego
Raised: $53 million
Investors: Enterprise Partners Venture Capital, GBS Venture Partners, H&Q Healthcare Investors, Hambrecht & Quist Capital Management, Johnson & Johnson Development Corporation, Lundbeckfond Ventures, MPM Capital, Novartis Venture Funds, Pfizer Venture Investments, Venrock Associates, and an undisclosed investor.
The scoop: The money is being used to engineer late-stage work on Mydicar, a heart failure treatment that recently gained fast-track status at the FDA. It also marks a major milestone for Celladon, which announced 5 years ago that it had raised $30 million from Kleiner Perkins and others to get Mydicar into the clinic.
Editor's note: This story has been updated with new information from Thomson Reuters.